<?xml version='1.0' encoding='utf-8'?>
<document id="26571227"><sentence text="Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving."><entity charOffset="0-9" id="DDI-PubMed.26571227.s1.e0" text="Bilastine" /></sentence><sentence text="Rational selection of a second-generation H1-antihistamine requires efficacy and safety considerations, particularly regarding central nervous system (CNS) effects (cognitive and psychomotor function), potential for driving impairment, minimal sedative effects and a lack of interactions" /><sentence text=" This review evaluates the key safety features of the non-sedating antihistamine, bilastine, during driving and in preventing road traffic accidents"><entity charOffset="82-91" id="DDI-PubMed.26571227.s3.e0" text="bilastine" /></sentence><sentence text="" /><sentence text="Among the second-generation H1-antihistamines, sedative effects which can affect cognitive and psychomotor performance, and possibly driving ability, may not be similar" /><sentence text=" Bilastine is absorbed rapidly, undergoes no hepatic metabolism or cytochrome P450 interaction (minimal drug-drug interaction potential), and is a substrate for P-glycoprotein (limiting CNS entry)"><entity charOffset="1-10" id="DDI-PubMed.26571227.s6.e0" text="Bilastine" /></sentence><sentence text=" Positron emission tomography showed that, compared with other second-generation H1-antihistamines, bilastine has the lowest cerebral histamine H1-receptor occupancy"><entity charOffset="81-98" id="DDI-PubMed.26571227.s7.e0" text="H1-antihistamines" /><entity charOffset="100-109" id="DDI-PubMed.26571227.s7.e1" text="bilastine" /><entity charOffset="134-143" id="DDI-PubMed.26571227.s7.e2" text="histamine" /><pair ddi="false" e1="DDI-PubMed.26571227.s7.e0" e2="DDI-PubMed.26571227.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26571227.s7.e0" e2="DDI-PubMed.26571227.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26571227.s7.e0" e2="DDI-PubMed.26571227.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26571227.s7.e1" e2="DDI-PubMed.26571227.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26571227.s7.e1" e2="DDI-PubMed.26571227.s7.e2" /></sentence><sentence text=" Bilastine 20Â mg once daily (therapeutic dose) is non-sedating, does not enhance the effects of alcohol or CNS sedatives, does not impair driving performance and has at least similar efficacy as other second-generation H1-antihistamines in the treatment of allergic rhinoconjunctivitis and urticaria"><entity charOffset="1-10" id="DDI-PubMed.26571227.s8.e0" text="Bilastine" /><entity charOffset="96-103" id="DDI-PubMed.26571227.s8.e1" text="alcohol" /><pair ddi="false" e1="DDI-PubMed.26571227.s8.e0" e2="DDI-PubMed.26571227.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26571227.s8.e0" e2="DDI-PubMed.26571227.s8.e1" /></sentence><sentence text="" /><sentence text="Current evidence shows that bilastine has an optimal benefit-to-risk ratio, meeting all conditions for contributing to safety in drivers who need antihistamines, and hence for being considered as an antihistamine of choice for drivers"><entity charOffset="28-37" id="DDI-PubMed.26571227.s10.e0" text="bilastine" /></sentence><sentence text="" /></document>